BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Research

• Publication date

  2016-01-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1541-7786.MCR-15-0472PMID 26792867PMCID PMC4834259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Mechanisms of the androgen receptor splicing in prostate cancer cells

  2014cited by this paper
• Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

  2014influential reference
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014influential reference
• Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

  2013cited by this paper
• Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

  2013cited by this paper
• Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  2013cited by this paper
• Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

  2013cited by this paper
• Overcoming mutation-based resistance to antiandrogens with rational drug design

  2013cited by this paper
• ARN-509: a novel antiandrogen for prostate cancer treatment.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

  2012cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• VCaP, a cell-based model system of human prostate cancer.

  2001cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995influential reference
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC

  2026cites this paper
• Bromodomain and extra-terminal proteins in solid tumors: regulators of immune microenvironment and emerging therapeutic targets

  2026cites this paper
• MBD3 increased expression by BRD4 and facilitated castration-resistant prostate cancer cell proliferation by inhibiting PTEN.

  2026cites this paper
• Restraining SRD5A1 combined with BRD4 inhibitor delaying prostate cancer progression by decreasing AR expression.

  2025cites this paper
• Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models

  2025cites this paper
• Epigenetic reprogramming as the nexus of cancer stemness and therapy resistance: implications for biomarker discovery

  2025cites this paper
• Epigenetic Approaches to Prostate Cancer: Present Landscape and Future Prospects.

  2025cites this paper
• Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance

  2025cites this paper
• Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer

  2025cites this paper
• Bromodomain and Extra-Terminal Family Proteins BRD2, BRD3, and BRD4 Contribute to H19-Dependent Transcriptional Regulation of Cell Adhesion Molecules, Modulating Metastatic Dissemination Program in Prostate Cancer

  2025cites this paper
• PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression

  2024cites this paper
• Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer.

  2024cites this paper
• Recent advances in basic research on prostate cancer: Where we are heading?

  2024cites this paper
• Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review

  2024cites this paper
• Role of bromodomain and extraterminal (BET) proteins in prostate cancer

  2023cites this paper
• Recent advances in epigenetic anticancer therapeutics and future perspectives

  2023cites this paper
• Epigenetic (De)regulation in Prostate Cancer.

  2023cites this paper
• CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.

  2023cites this paper
• An intricate rewiring of cancer metabolism via alternative splicing.

  2023cites this paper
• Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance

  2023cites this paper
• Exploiting epigenetic targets to overcome taxane resistance in prostate cancer

  2023cites this paper
• Functional implications and therapeutic targeting of androgen response elements in prostate cancer.

  2023cites this paper
• Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution

  2023cites this paper
• Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy

  2023cites this paper
• Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.

  2023cites this paper
• Characterizing crosstalk in epigenetic signaling to understand disease physiology.

  2023cites this paper
• Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition

  2022cites this paper
• Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

  2022influential citation
• Epigenetics and precision medicine in prostate cancer

  2022cites this paper
• Physachenolide C is a Potent, Selective BET Inhibitor.

  2022cites this paper
• ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin

  2022cites this paper
• Identification of the gossypol derivatives as androgen receptor inhibitor.

  2022cites this paper
• New approaches to targeting epigenetic regulation in prostate cancer

  2022cites this paper
• SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy

  2021cites this paper
• Improving strategies in the development of protein-downregulation based antiandrogens.

  2021cites this paper
• Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold

  2021cites this paper
• Targeting p300/CBP axis in lethal prostate cancer.

  2021cites this paper
• Targeting p300/CBP in lethal prostate cancer

  2021cites this paper
• BET Proteins as Attractive Targets for Cancer Therapeutics

  2021cites this paper
• Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention

  2021cites this paper
• Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response

  2021cites this paper
• Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer

  2021cites this paper
• Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

  2021cites this paper
• AR Splicing Variants and Resistance to AR Targeting Agents

  2021cites this paper
• Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• Epigenetics in prostate cancer: clinical implications

  2021cites this paper
• Advances in epigenetic therapeutics with focus on solid tumors

  2021cites this paper
• Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends

  2021cites this paper
• Targeting treatment options for castration-resistant prostate cancer.

  2021cites this paper
• The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.

  2021cites this paper
• Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.

  2021cites this paper
• Resistance to second-generation androgen receptor antagonists in prostate cancer

  2021cites this paper
• The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models

  2021cites this paper
• Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

  2021cites this paper
• JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

  2021cites this paper
• Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.

  2020cites this paper
• The emerging role of BET inhibitors in breast cancer

  2020cites this paper
• Domain-selective targeting of BET proteins in cancer and immunological diseases.

  2020cites this paper
• Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

  2020cites this paper
• Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

  2020cites this paper
• Metabolically Stable Diphenylamine Derivatives Suppress Androgen Receptor and BET Protein in Prostate Cancer.

  2020cites this paper
• Androgen receptor variant-driven prostate cancer II: advances in clinical investigation

  2020cites this paper
• Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

  2020cites this paper
• Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer

  2020cites this paper
• Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer

  2020cites this paper
• Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression

  2020cites this paper
• Title: Targeting p300/CBP in lethal prostate cancer. Running title: Targeting p300/CBP in lethal prostate cancer

  2020cites this paper
• Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets

  2020cites this paper
• Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer

  2019cites this paper
• Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

  2019cites this paper
• Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer.

  2019cites this paper
• Targeting the androgen receptor and overcoming resistance in prostate cancer

  2019cites this paper
• Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer

  2019cites this paper
• KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.

  2019cites this paper
• Targeting Cancer at the Intersection of Signaling and Epigenetics

  2019cites this paper
• Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells

  2019cites this paper
• BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK

  2019cites this paper
• Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

  2019cites this paper
• Bromodomains: a new target class for drug development

  2019cites this paper
• Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma.

  2019cites this paper
• Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer.

  2019cites this paper
• Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

  2019influential citation
• Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer.

  2019cites this paper
• CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation.

  2019cites this paper
• Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

  2019cites this paper
• Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

  2019cites this paper
• Towards precision oncology in advanced prostate cancer

  2019cites this paper
• The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.

  2019influential citation
• Epigenetic Regulation of Chromatin in Prostate Cancer.

  2019cites this paper
• ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 (AR-V7) in castrate-resistant prostate cancer

  2018cites this paper
• IDENTIFYING MOLECULAR TARGETS AND VALIDATING NOVEL THERAPIES FOR OVARIAN CANCER

  2018cites this paper
• BET Proteins as Targets for Anticancer Treatment.

  2018cites this paper
• ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

  2018cites this paper
• Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

  2018cites this paper
• Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.

  2018cites this paper
• Bromodomain and Extraterminal Domain (BET) Inhibitor RVX-208 Ameliorates Periodontal Bone Loss

  2018cites this paper
• Current and potential targets for drug design in the androgen receptor pathway for prostate cancer

  2018cites this paper
• Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

  2018cites this paper
• LSD1: A single target to combat lineage plasticity in lethal prostate cancer

  2018cites this paper